TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06402890

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistance training with collagen supplementation
Description: Participants performed 24 lower limb resistance training sessions over under supervision from the principal investigator. Participants were pair-matched, then allocated to hydrolysed collagen (COL) or a calorie-matched beverage comprising maltodextrin and non-caloric sweetener (PLA). Both COL and PLA consumed their respective supplements in conjunction with each resistance training session.~Baseline assessments of strength were used to set initial training loads. An example of weekly training is included below for indicative purposes:~Week 1 protocol:~Day 1:~* Barbell squat, 4 sets @ 90% 10-RM~* Romanian deadlift, 4 sets @ 90% 10-RM~Day 2:~* Hex bar deadlift, 4 sets @ 90% 10-RM~* Dumbbell goblet squat, 4 sets @ 90% 10-RM~Linear progression adjusted weekly loads. If participants completed the prescribed sets and reps, loads increased by 2.5-5 % the following week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistance training with collagen supplementation
Description: Participants performed 24 lower limb resistance training sessions over under supervision from the principal investigator. Participants were pair-matched, then allocated to hydrolysed collagen (COL) or a calorie-matched beverage comprising maltodextrin and non-caloric sweetener (PLA). Both COL and PLA consumed their respective supplements in conjunction with each resistance training session.~Baseline assessments of strength were used to set initial training loads. An example of weekly training is included below for indicative purposes:~Week 1 protocol:~Day 1:~* Barbell squat, 4 sets @ 90% 10-RM~* Romanian deadlift, 4 sets @ 90% 10-RM~Day 2:~* Hex bar deadlift, 4 sets @ 90% 10-RM~* Dumbbell goblet squat, 4 sets @ 90% 10-RM~Linear progression adjusted weekly loads. If participants completed the prescribed sets and reps, loads increased by 2.5-5 % the following week.
Study: NCT05898087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine 0.25 % Injectable Solution
Description: Patients in this arm will receive an injection of 20cc of injectable 0.25% bupivacaine solution. It will be injected in a fan-like pattern beneath the pectoralis fascia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in this arm will receive an injection of 20cc of injectable saline. It will be injected in a fan-like pattern beneath the pectoralis fascia
Study: NCT06210789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision
Description: Periodontal plastic reconstruction of the subsequent soft tissue dehiscence after the surgical excision of the localized gingival enlargement
Study: NCT05575999

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
Description: The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
Description: The plan will be to stratify patients in two groups: intervention group receiving 20 cc combination of BKK (Bupivacaine HCl 60 mg \[3 mg/mL\], Ketorolac Tromethamine 24 mg \[1.2mg/mL\], Ketamine HCl 24 mg \[1.2 mg/mL\]) vs the control group receiving 20 cc of 0.5% bupivacaine (Bupivacaine HCL 100 mg \[5mg/ml\]. The dose can be repeated multiple times during the procedure as per operator's discretion. The patients will be further stratified into sub-groups based on type of procedure they had undergone. Analgesia/anesthesia strategy will be local infiltration of the drug along with a sedating agent based on institutional standard of care. The dose of the medicines will be adjusted as per discretion of the operator to maintain adequate anesthesia/analgesia during and after the procedure.
Study: NCT06003855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Description: Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise therapy
Description: Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
Study: NCT05007483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BodyBio Balance Oil
Description: nutraceutical supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BodyBio Balance Oil
Description: nutraceutical supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kirunal Fish Oil
Description: nutraceutical supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kirunal Fish Oil
Description: nutraceutical supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BodyBio PC
Description: nutraceutical supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BodyBio PC
Description: nutraceutical supplement
Study: NCT06539208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YOLT-201
Description: Infusion of YOLT-201 at Day 1
Study: NCT05266053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO 7 dressing
Description: The PICO 7 dressing consists of a negative pressure wound therapy pump (NPWT) connected to an absorbent gentle adhesive dressing that is applied to a wound. When the pump is activated, it acts by pulling excess fluid from the wound. The dressing absorbs this fluid and helps to prevent bacteria from entering the wound. It has been shown to prevent wound infections and promote healing.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard wound dressing
Description: Standard abdominal dressing at the time of cesarean
Study: NCT06582576

Intervention type: DIAGNOSTIC_TEST
Intervention: Effect of different gastric electrical stimulator stimulation paragdimes on brain, heart, and stomach.
Description: Measuring EEG, ECG, and ultrasound in both groups during different stimulation intensities provided by the previously implanted gastric electrical stimulator.

Intervention type: DIAGNOSTIC_TEST
Intervention: Effect of different gastric electrical stimulator stimulation paragdimes on brain, heart, and stomach.
Description: Measuring EEG, ECG, and ultrasound in both groups during different stimulation intensities provided by the previously implanted gastric electrical stimulator.
Study: NCT05007483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Paleolithic Elimination diet
Description: 1. Complete elimination of all gluten-, dairy-, and egg-containing foods.~2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.~3. Consume 6-12 ounces/day protein including organ meats and fatty fish.~4. Consume fermented foods daily.~5. Consume daily servings of algae, seaweed, and nutritional yeast.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Olive Oil Based (TROO) Ketogenic Diet
Description: 1. Restriction of dietary carbohydrates to \< 50 grams/day.~2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to \>160 grams/day.~3. Consume \<100 grams/day protein.~4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).~5. Consume at least 3 servings/day non-starchy vegetables.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet with Dietary Guidelines for Americans Diet information
Description: 1. Limit sodium to \< 2,300 mg/day.~2. Limit added sugar and saturated fat intake to \<10% of kcal/day, respectively.~3. Consume 5 servings of fruits and vegetables per day.~4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.~5. Consume 3 servings of reduced fat dairy per day.~6. Consume 6 ounces/day protein foods.
Study: NCT06126549

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Building Better Caregivers
Description: Peer-led, group intervention for caregivers focused on problem-solving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Training
Description: Clinician-led, one-to-one intervention for caregivers focused on problem-solving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual discharge training and support offered to family caregivers of ABI patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual discharge training and support offered to family caregivers of ABI patients

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual discharge training and support offered to family caregivers of ABI patients
Study: NCT06333938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge
Description: Percutaneous Nerve Field Stimulation using a disposable battery operated and device, approved by the FDA for the treatment of clinical symptoms related to opioid withdrawal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BFA
Description: BFA is an auricular acupuncture technique (developed within the VA/ DoD health systems) delivered by providers using 1mm acupuncture needles.
Study: NCT06196970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilate exercises
Description: After 10 minutes of warmup excercises, participatants perform pilates exercises, Pelvic curl : 45 seconds hold The Hundred : 45 seconds hold Bird Dog : 45 seconds hold Side plank : 45 seconds hold Frequency 3 days a week intensity 45 minutes hold a pose. Time will be 10 to 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burpees exercises
Description: After 10 minutes of warmup excercises, participatants perform burppes excercises.~1. Stand straight with your feet shoulder-width apart.~2. Squat and place your hands in front of your feet.~3. Jump back until your legs are fully extended and your body is in plank position.~4. Do a push up, jump forward, and then push through the heels to return to the starting position.~5. Repeat until the set is complete. Frequency 3 days a week .Time 10 to 15 minutes with 10 reputation , 3 sets. Rest internal will be 10 seconds after each set.
Study: NCT05443503

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile health applications (mHealth apps) based intervention
Description: Patients can choose among or choose to be assigned to 2 tracks for management for their low back pain. The tracks include one focused on relaxation and symptom management, and another track on increasing activity. Each include educational material adapted from various sources from North America Spine Society (NASS), Center for Disease Control (CDC), National Institue of Health (NIH). Patients will stay in track for 28 days. After this, they may choose to remain in track and continue to perform maintenance activities or to engage in a different track.
Study: NCT04793152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Administration as outlined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Administration as outlined
Study: NCT04974593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat diet
Description: A trained dietitian will provide instruction of the LFD according to standard practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fat diet
Description: A trained dietitian will provide instruction of the LFD according to standard practice.
Study: NCT05198349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1069
Description: Participants received escalated oral dose of M1069, twice daily (BID) until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from study intervention.
Study: NCT06076538

Intervention type: DIAGNOSTIC_TEST
Intervention: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging
Description: PET/MR scan utilizing FDG Radiopharmaceutical
Study: NCT05159713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBI
Description: The dCBI, RxWell, is a trans-CBT mobile app product addressing depression and anxiety that was developed based on standard CBT techniques. RxWell provides users users with 40 brief (5-10 minute) skill building techniques for anxiety and depression. Users will have access to a goal-setting tab and in the moment relief section which contains over 17 techniques,14 of which are brief audios to help users engage relaxation responses. The user will be provided with the depression path, which has 40 unique techniques, and if the user expresses significant anxiety, the coach will have the ability to personalize the program by pulling in any of the 53 techniques from the anxiety path, so that the individual can utilize the proper CBT techniques that fit with their presentation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
Study: NCT06648499

Intervention type: OTHER
Intervention: Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in POMS
Description: The demographic information of the patients will be taken with the form prepared for the people in this group. Patients will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
Study: NCT06041477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
Description: Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU
Description: Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs, 5-FU 2400mg/m2 over 46hrs,every 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent Lenvatinib
Description: Lenvatinib 8mg/day combined with the HAIC from the first cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent PD-1 antibody
Description: PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the first cycle (dosage and frequency according to instructions)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Lenvatinib
Description: Lenvatinib 8mg/day combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR)
Study: NCT05759143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nest Platform
Description: Patient- and clinician-facing portal via secure link
Study: NCT06648499

Intervention type: OTHER
Intervention: Evaluation of lower extremity muscle strength, physical activity, exercise capacity, balance, quality of life, and fatigue in healthy controls
Description: The demographic information of the healthy controls will be taken. Healthy controls will be assessed using the FTSTS test to evaluate lower extremity muscle strength, the Godin Leisure Time Exercise Questionnaire (GLTEQ) for physical activity, the 2-Minute Walk Test (2MWT) for exercise capacity, the Timed Up and Go (TUG) Test for functional mobility, the Pediatric Quality of Life Inventory (PedsQL) for quality of life, and the PedsQL Multidimensional Fatigue Scale for fatigue. All assessments will be completed on the same day and will not be repeated after a certain period of time.
Study: NCT05784311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Description: 1500mg IV cefuroxime thrice daily during five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 500mg IV metronidazole thrice daily during five days.
Study: NCT05228990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: warm acupunctrue
Description: The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: warm acupunctrue
Description: The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to get qi, moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes.
Study: NCT06014008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test product consumption group
Description: Participants will take one bottle (80 ml) of Yakult® drink daily for a period of 4 weeks. Yakult is a branded probiotic drink with 8x10\^9 CFU Lacticaseibacillus paracasei strain Shirota. Subsequently, a two-week follow-up period will follow.
Study: NCT05008211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information-Motivation-Behavioral skills (IMB) model-based intervention
Description: A six-week programme
Study: NCT06099886

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lithium aspartate
Description: Lithium aspartate 30-45mg/day
Study: NCT05675930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation/PBM (via Thor LX2.3 system device) for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sham device
Description: Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days
Study: NCT05008211

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - usual care
Description: he nurse will provide an one-hour face-to-face session to introduce the choices of domiciliary NIV and teach the patient or his/her family on how to operate and maintain the ventilator, interface and accessories, and also how to handle the common problems
Study: NCT05667012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational videos
Description: There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational videos
Description: There will be a total of 6 videos, each of these videos will last between 8 and 10 minutes and will be accessed through a YouTube link to a private channel.
Study: NCT05658731

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: substructure informed planning
Description: Radiation Therapy with substructure informed planning determined by the PI.
Study: NCT06041477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential PD-1 antibody
Description: PD-1 antibody which is approved by authorities for HCC treatment combined with the HAIC from the third cycle for those patients who do not achieve complete response (CR) (dosage and frequency according to instructions)